Sharon R. Weeks
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sharon R. Weeks has a total of 220 co-authors. Here are the top co-authors by number of shared publications:
- Jack W. Tsao
Department of Neurology Langone School of Medicine New York University United States
6 shared publications Jack W. Tsao
4 shared publicationsPaul F. Pasquina
Walter Reed National Military Medical Center, Bethesda, MD, United States
4 shared publications- Andrew MacGregor Cameron
Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
3 shared publications Benjamin Philosophe
Department of Surgery Johns Hopkins School of Medicine Baltimore Maryland USA
3 shared publications- Paul F. Pasquina
Department of Physical Medicine and Rehabilitation, Uniformed Services University, Bethesda, MD 20814, USA
3 shared publications
Latest Publications
- Open Access
Renal Trajectory of Eligible Simultaneous Liver–Kidney Transplant Recipients
Purpose: Simultaneous liver–kidney transplantation (SLK) eligible candidates may receive SLK or liver-alone transplant (LA) with access to kidney transplant after initial LA (KAL). We aimed to characterize SLK-eligible recipient outcomes according to treatment approach. Methods: This study utilized 2017–2023 SRTR data to identify SLK-eligible deceased donor liver transplants. Recipients were placed into two groups based on whether SLK was performed; non-SLK patients were sub-stratified into LA and KAL cohorts. After baseline comparisons, 2-year patient and graft survival outcomes were characterized by univariable and multivariable Cox proportional hazard regression and Kaplan–Meier analysis. Results: Among 4879 candidates identified, 3746 (76.8%) underwent SLK, 1023 (21.0%) LA, and 110 (2.3%) KAL. SLK recipients maintained the highest eGFRs at 6 months, 1 year, and 2 years post-transplant (p < 0.01). Compared to SLK recipients, non-SLK recipients had a higher 2-year risk of mortality (aHR 2.46, p < 0.01), all-cause events (aHR 1.91, p < 0.01), and liver graft failure (HR 1.55, p = 0.02). LA conferred a higher 2-year mortality risk (aHR 2.98, p < 0.01) and all-cause event risk (aHR 2.25, p < 0.01), while KAL had comparable mortality risk to SLK (aHR 0.43, p = 0.40). Conclusions: When SLK-eligible candidates undergo transplants, SLK remains the optimal path forward, even when a safety net kidney can be performed.
Open AccessRenal Trajectory of Eligible Simultaneous Liver–Kidney Transplant Recipients
Purpose: Simultaneous liver–kidney transplantation (SLK) eligible candidates may receive SLK or liver-alone transplant (LA) with access to kidney transplant after initial LA (KAL). We aimed to characterize SLK-eligible recipient outcomes according to treatment approach. Methods: This study utilized 2017–2023 SRTR data to identify SLK-eligible deceased donor liver transplants. Recipients were placed into two groups based on whether SLK was performed; non-SLK patients were sub-stratified into LA and KAL cohorts. After baseline comparisons, 2-year patient and graft survival outcomes were characterized by univariable and multivariable Cox proportional hazard regression and Kaplan–Meier analysis. Results: Among 4879 candidates identified, 3746 (76.8%) underwent SLK, 1023 (21.0%) LA, and 110 (2.3%) KAL. SLK recipients maintained the highest eGFRs at 6 months, 1 year, and 2 years post-transplant (p < 0.01). Compared to SLK recipients, non-SLK recipients had a higher 2-year risk of mortality (aHR 2.46, p < 0.01), all-cause events (aHR 1.91, p < 0.01), and liver graft failure (HR 1.55, p = 0.02). LA conferred a higher 2-year mortality risk (aHR 2.98, p < 0.01) and all-cause event risk (aHR 2.25, p < 0.01), while KAL had comparable mortality risk to SLK (aHR 0.43, p = 0.40). Conclusions: When SLK-eligible candidates undergo transplants, SLK remains the optimal path forward, even when a safety net kidney can be performed.
- 9 June 2025
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 31 (12) , 1472-1487
Access to early liver transplantation is adversely impacted by social determinants of health: A retrospective cohort study
Early liver transplant (ELT) is the practice of liver transplant for those with severe alcohol-associated hepatitis or acute on chronic alcohol-associated liver disease, without requiring any minimum pre-transplant abstinence period. It is an increasingly adopted practice for alcohol-associated liver disease (ALD) capable of providing excellent outcomes, but there are concerns regarding equity in access to ELT. Our objectives were 1) to quantify the association between social determinants of health (SDoH) and progression from referral to listing, and 2) to identify geographic disparities in referrals for ELT. We included 501 ELT candidates and a comparison population of 165 SLT candidates referred from 2017 until 2023. Multivariable regression quantified the association between individual- and neighborhood-level SDoH and progression from referral to listing, adjusting for sociodemographic characteristics and MELD. Negative binomial regression quantified the association between neighborhood-level SDoH and the number of ELT referrals within 150Nmi of our institution, adjusting for relevant geographic confounders. ELT candidates with Medicaid insurance were less likely to progress from referral to evaluation than candidates with private insurance (RR 0.69, 95% CI 0.56-0.85). ELT candidates from census tracts with a high social vulnerability index (SVI) were less likely to progress from evaluation to listing than candidates from low SVI census tracts in Modified Poisson Regression (RR 0.64, 95% CI 0.46-0.88), but not in Cox regression (HR 0.67, 95% CI 0.41-1.09). These findings were not significant among SLT candidates. High SVI census tracts were less likely to have individuals referred for ALD compared to tracts with low SVI (IRR 0.53, 95% CI 0.42-0.66). Both individual- and neighborhood-level SDoH are important factors that ultimately influence who is eligible for transplant. Export
- 9 June 2025
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 31 (12) , 1472-1487
Access to early liver transplantation is adversely impacted by social determinants of health: A retrospective cohort study
Early liver transplant (ELT) is the practice of liver transplant for those with severe alcohol-associated hepatitis or acute on chronic alcohol-associated liver disease, without requiring any minimum pre-transplant abstinence period. It is an increasingly adopted practice for alcohol-associated liver disease (ALD) capable of providing excellent outcomes, but there are concerns regarding equity in access to ELT. Our objectives were 1) to quantify the association between social determinants of health (SDoH) and progression from referral to listing, and 2) to identify geographic disparities in referrals for ELT. We included 501 ELT candidates and a comparison population of 165 SLT candidates referred from 2017 until 2023. Multivariable regression quantified the association between individual- and neighborhood-level SDoH and progression from referral to listing, adjusting for sociodemographic characteristics and MELD. Negative binomial regression quantified the association between neighborhood-level SDoH and the number of ELT referrals within 150Nmi of our institution, adjusting for relevant geographic confounders. ELT candidates with Medicaid insurance were less likely to progress from referral to evaluation than candidates with private insurance (RR 0.69, 95% CI 0.56-0.85). ELT candidates from census tracts with a high social vulnerability index (SVI) were less likely to progress from evaluation to listing than candidates from low SVI census tracts in Modified Poisson Regression (RR 0.64, 95% CI 0.46-0.88), but not in Cox regression (HR 0.67, 95% CI 0.41-1.09). These findings were not significant among SLT candidates. High SVI census tracts were less likely to have individuals referred for ALD compared to tracts with low SVI (IRR 0.53, 95% CI 0.42-0.66). Both individual- and neighborhood-level SDoH are important factors that ultimately influence who is eligible for transplant. Export
- 7 July 2024
- Published by Wiley in Transplant Infectious Disease
- Vol. 26 (S1) , e14334
HHV‐8‐associated diseases in transplantation: A case report and narrative review focused on diagnosis and prevention
Background: Human herpes virus 8 (HHV‐8) or Kaposi sarcoma herpesvirus (KSHV) is an opportunistic oncovirus that causes multiple pathologic entities.Methods: We present a case of fatal HHV‐8‐associated multisystem illness with disseminated Kaposi sarcoma and HHV8‐associated lymphoproliferative disorder with systemic inflammation. We conducted a narrative review of the literature on HHV‐8 in transplantation with a goal of illuminating the spectrum of HHV‐8‐associated diseases in this vulnerable population, modes of disease transmission, and the potential role for donor and recipient screening.Results: HHV‐8‐associated KS, primary effusion lymphoma (PEL), multicentric Castleman disease (MCD), and KSHV inflammatory cytokine disorder (KICS) may affect transplant recipients; with the exception of KS, these conditions are rare but carry high morbidity and mortality.Conclusion: HHV‐8‐associated diseases have diverse and protean manifestations in transplant recipients, with potentially fatal outcomes. HHV‐8 seroprevalence among organ donors and the magnitude of risk for donor‐derived HHV‐8 infection or clinically significant disease remain unknown and require further study. image
- 7 July 2024
- Published by Wiley in Transplant Infectious Disease
- Vol. 26 (S1) , e14334
HHV‐8‐associated diseases in transplantation: A case report and narrative review focused on diagnosis and prevention
Background: Human herpes virus 8 (HHV‐8) or Kaposi sarcoma herpesvirus (KSHV) is an opportunistic oncovirus that causes multiple pathologic entities.Methods: We present a case of fatal HHV‐8‐associated multisystem illness with disseminated Kaposi sarcoma and HHV8‐associated lymphoproliferative disorder with systemic inflammation. We conducted a narrative review of the literature on HHV‐8 in transplantation with a goal of illuminating the spectrum of HHV‐8‐associated diseases in this vulnerable population, modes of disease transmission, and the potential role for donor and recipient screening.Results: HHV‐8‐associated KS, primary effusion lymphoma (PEL), multicentric Castleman disease (MCD), and KSHV inflammatory cytokine disorder (KICS) may affect transplant recipients; with the exception of KS, these conditions are rare but carry high morbidity and mortality.Conclusion: HHV‐8‐associated diseases have diverse and protean manifestations in transplant recipients, with potentially fatal outcomes. HHV‐8 seroprevalence among organ donors and the magnitude of risk for donor‐derived HHV‐8 infection or clinically significant disease remain unknown and require further study. image
- 27 July 2023
- Published by Wiley in Clinical Transplantation
- Vol. 37 (9) , e15081
Successful liver transplantation from deceased donors with active COVID‐19 infections with undetectable SARS‐CoV‐2 in donor liver and aorta
The COVID-19 pandemic, caused by the SARS-CoV-2 virus, has had unprecedented effects on society and modern healthcare. In liver transplantation, uncertainty regarding the safety of performing transplants during the early stage of the pandemic resulted in increased waitlist mortality. Additionally, concerns about disease transmission led to avoidance of deceased donors with COVID-19 infections. Several successful case reports describing incidental transplant of organs from donors with COVID-19 infections or intentional transplant of such donors into recipients with current or prior COVID-19 infections prompted the transplant community to re-evaluate that position. While excellent short-term results have been published, little is known about use of donors with active infections and the extent of COVID-19 organ involvement, which may affect long term outcomes. We report the successful transplantation of three livers from deceased donors with active COVID-19 infections. Donor liver and aortic tissues were evaluated by sensitive molecular testing for SARS-CoV-2 RNA via in situ hybridization and real-time quantitative reverse transcription PCR. Postoperatively, all patients had excellent allograft function, without clinical or molecular evidence of SARS-CoV-2 transmission in donor tissues. This evidence supports the use of liver donors with active COVID-19 infections.
- 27 July 2023
- Published by Wiley in Clinical Transplantation
- Vol. 37 (9) , e15081
Successful liver transplantation from deceased donors with active COVID‐19 infections with undetectable SARS‐CoV‐2 in donor liver and aorta
The COVID-19 pandemic, caused by the SARS-CoV-2 virus, has had unprecedented effects on society and modern healthcare. In liver transplantation, uncertainty regarding the safety of performing transplants during the early stage of the pandemic resulted in increased waitlist mortality. Additionally, concerns about disease transmission led to avoidance of deceased donors with COVID-19 infections. Several successful case reports describing incidental transplant of organs from donors with COVID-19 infections or intentional transplant of such donors into recipients with current or prior COVID-19 infections prompted the transplant community to re-evaluate that position. While excellent short-term results have been published, little is known about use of donors with active infections and the extent of COVID-19 organ involvement, which may affect long term outcomes. We report the successful transplantation of three livers from deceased donors with active COVID-19 infections. Donor liver and aortic tissues were evaluated by sensitive molecular testing for SARS-CoV-2 RNA via in situ hybridization and real-time quantitative reverse transcription PCR. Postoperatively, all patients had excellent allograft function, without clinical or molecular evidence of SARS-CoV-2 transmission in donor tissues. This evidence supports the use of liver donors with active COVID-19 infections.
- 11 July 2020
- Published by Wiley in Clinical Transplantation
- Vol. 34 (10) , e14036
Steroid‐sparing maintenance immunosuppression is safe and effective after simultaneous liver‐kidney transplantation
Optimization of maintenance immunosuppression (mIS) regimens in the transplant recipient requires a balance between sufficient potency to prevent rejection and avoidance of excessive immunosuppression to prevent toxicities and complications. The optimal regimen after simultaneous liver‐kidney (SLK) transplantation remains unclear, but small single‐center reports have shown success with steroid‐sparing regimens. We studied 4184 adult SLK recipients using the Scientific Registry of Transplant Recipients, from March 1, 2002, to February 28, 2017, on tacrolimus‐based regimens at 1 year post‐transplant. We determined the association between mIS regimen and mortality and graft failure using Cox proportional hazard models. The use of steroid‐sparing regimens increased post‐transplant, from 16.1% at discharge to 88.0% at 5 years. Using multi‐level logistic regression modeling, we found center‐level variation to be the major contributor to choice of mIS regimen (ICC 44.5%; 95% CI: 36.2%‐53.0%). In multivariate analysis, use of a steroid‐sparing regimen at 1 year was associated with a 21% decreased risk of mortality compared to steroid‐containing regimens (aHR 0.79, P = .01) and 20% decreased risk of liver graft failure (aHR 0.80, P = .01), without differences in kidney graft loss risk (aHR 0.92, P = .6). Among SLK recipients, the use of a steroid‐sparing regimen appears to be safe and effective without adverse effects on patient or graft survival.
- 11 July 2020
- Published by Wiley in Clinical Transplantation
- Vol. 34 (10) , e14036
Steroid‐sparing maintenance immunosuppression is safe and effective after simultaneous liver‐kidney transplantation
Optimization of maintenance immunosuppression (mIS) regimens in the transplant recipient requires a balance between sufficient potency to prevent rejection and avoidance of excessive immunosuppression to prevent toxicities and complications. The optimal regimen after simultaneous liver‐kidney (SLK) transplantation remains unclear, but small single‐center reports have shown success with steroid‐sparing regimens. We studied 4184 adult SLK recipients using the Scientific Registry of Transplant Recipients, from March 1, 2002, to February 28, 2017, on tacrolimus‐based regimens at 1 year post‐transplant. We determined the association between mIS regimen and mortality and graft failure using Cox proportional hazard models. The use of steroid‐sparing regimens increased post‐transplant, from 16.1% at discharge to 88.0% at 5 years. Using multi‐level logistic regression modeling, we found center‐level variation to be the major contributor to choice of mIS regimen (ICC 44.5%; 95% CI: 36.2%‐53.0%). In multivariate analysis, use of a steroid‐sparing regimen at 1 year was associated with a 21% decreased risk of mortality compared to steroid‐containing regimens (aHR 0.79, P = .01) and 20% decreased risk of liver graft failure (aHR 0.80, P = .01), without differences in kidney graft loss risk (aHR 0.92, P = .6). Among SLK recipients, the use of a steroid‐sparing regimen appears to be safe and effective without adverse effects on patient or graft survival.
- Open Access
- 1 January 2019
- Published by Elsevier in NeuroImage: Clinical
- Vol. 23, 101882
Visual responsiveness in sensorimotor cortex is increased following amputation and reduced after mirror therapy
- 1 January 2019
- Published by Elsevier in NeuroImage: Clinical
- Vol. 23, 101882
Open AccessVisual responsiveness in sensorimotor cortex is increased following amputation and reduced after mirror therapy
- 1 May 2018
- Published by Elsevier in Gastroenterology
- Vol. 154 (6)
Sa1544 - Impact of Pre Versus Post Liver Transplant HCV Treatment with Direct-Acting Antivirals on Post Liver Transplant Survival
- 1 May 2018
- Published by Elsevier in Gastroenterology
- Vol. 154 (6)
Sa1544 - Impact of Pre Versus Post Liver Transplant HCV Treatment with Direct-Acting Antivirals on Post Liver Transplant Survival
- 1 April 2018
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
- Vol. 226 (4) , 549-557
Liver Transplantation for Severe Alcoholic Hepatitis, Updated Lessons from the World's Largest Series
Six-month sobriety before transplantation for alcoholic liver disease is typically required but poorly supported by data. We initiated a pilot program after a report of liver transplantation for severe alcoholic hepatitis (SAH) in which the 6-month rule was waived. We previously reported early outcomes; we now provide longer follow-up in the largest cohort of early liver transplantation for SAH in the literature to date. Forty-six carefully selected patients with SAH underwent liver transplantation from October 2012 through July 2017; none had been abstinent for 6 months. We also examined 34 patients with alcoholic cirrhosis who received liver transplants under standard protocols with at least 6 months sobriety. We identified patient characteristics and primary outcomes of patient and graft survival, as well as alcohol recidivism. Secondary outcomes included post-transplantation infection, malignancy, and rejection. Compared with patients with alcoholic cirrhosis, SAH patients were younger and with shorter drinking history and higher Model for End-Stage Liver Disease scores at listing and at transplantation. Of these patients, 46% received preoperative steroids; all were nonresponders by Lille score. At a median follow-up time of 532 days (interquartile range 281 to 998 days), there were no significant differences between groups by log-rank testing of Kaplan-Meier estimates for patient and graft survival or alcohol recidivism. In the largest cohort of patients reported, outcomes after liver transplantation for SAH had excellent 1-year outcomes, similar to those seen in patients who received transplants with 6 months of sobriety. Recidivism was similar in the 2 groups. Early liver transplantation for SAH represents life-saving therapy for patients with otherwise high mortality, calling into question the utility of the 6-month rule in predicting outcomes in patients receiving transplants for alcoholic liver disease.
- 1 April 2018
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
- Vol. 226 (4) , 549-557
Liver Transplantation for Severe Alcoholic Hepatitis, Updated Lessons from the World's Largest Series
Six-month sobriety before transplantation for alcoholic liver disease is typically required but poorly supported by data. We initiated a pilot program after a report of liver transplantation for severe alcoholic hepatitis (SAH) in which the 6-month rule was waived. We previously reported early outcomes; we now provide longer follow-up in the largest cohort of early liver transplantation for SAH in the literature to date. Forty-six carefully selected patients with SAH underwent liver transplantation from October 2012 through July 2017; none had been abstinent for 6 months. We also examined 34 patients with alcoholic cirrhosis who received liver transplants under standard protocols with at least 6 months sobriety. We identified patient characteristics and primary outcomes of patient and graft survival, as well as alcohol recidivism. Secondary outcomes included post-transplantation infection, malignancy, and rejection. Compared with patients with alcoholic cirrhosis, SAH patients were younger and with shorter drinking history and higher Model for End-Stage Liver Disease scores at listing and at transplantation. Of these patients, 46% received preoperative steroids; all were nonresponders by Lille score. At a median follow-up time of 532 days (interquartile range 281 to 998 days), there were no significant differences between groups by log-rank testing of Kaplan-Meier estimates for patient and graft survival or alcohol recidivism. In the largest cohort of patients reported, outcomes after liver transplantation for SAH had excellent 1-year outcomes, similar to those seen in patients who received transplants with 6 months of sobriety. Recidivism was similar in the 2 groups. Early liver transplantation for SAH represents life-saving therapy for patients with otherwise high mortality, calling into question the utility of the 6-month rule in predicting outcomes in patients receiving transplants for alcoholic liver disease.
- Open Access
- 1 January 2018
- Published by American Medical Association (AMA) in JAMA Surgery
- Vol. 153 (1) , 84-86
Humanitarian Surgical Care in the US Military Treatment Facilities in Afghanistan From 2002 to 2013
Medical units of the US military have operated for more than 15 years in Afghanistan, a country with among the lowest estimates of access to safe, timely surgical and anesthesia care.1 Surgeons from the US military have delivered humanitarian surgical care (HSC) to local national civilians throughout the conflict, although previous large reports about this care focused on children.2,3 To provide a more comprehensive accounting, we conducted a retrospective study on HSC provided by deployed US military medical units to local national civilians during the Afghanistan conflict.
- 1 January 2018
- Published by American Medical Association (AMA) in JAMA Surgery
- Vol. 153 (1) , 84-86
Open AccessHumanitarian Surgical Care in the US Military Treatment Facilities in Afghanistan From 2002 to 2013
Medical units of the US military have operated for more than 15 years in Afghanistan, a country with among the lowest estimates of access to safe, timely surgical and anesthesia care.1 Surgeons from the US military have delivered humanitarian surgical care (HSC) to local national civilians throughout the conflict, although previous large reports about this care focused on children.2,3 To provide a more comprehensive accounting, we conducted a retrospective study on HSC provided by deployed US military medical units to local national civilians during the Afghanistan conflict.
- Open Access
- 7 July 2017
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 8, 267
A Randomized, Controlled Trial of Mirror Therapy for Upper Extremity Phantom Limb Pain in Male Amputees
Objective: Phantom limb pain is prevalent in patients post-amputation and is difficult to treat. We assessed the efficacy of mirror therapy in relieving phantom limb pain in unilateral, upper extremity male amputees. Methods: Fifteen participants from Walter Reed and Brooke Army Medical Centers were randomly assigned to one of two groups: mirror therapy (n=9) or control (n=6, covered mirror or mental visualization therapy). Participants were asked to perform 15 minutes of their assigned therapy daily for 5 days/week for four weeks. The primary outcome was pain as measured using a 100-mm Visual Analogue Scale (VAS). Results: Subjects in the mirror therapy group had a significant decrease in pain scores, from a mean of 44.1 (SD=17.0) to 27.5 (SD=17.2) mm (p=0.002). In addition, there was a significant decrease in daily time experiencing pain, from a mean of 1022 (SD=673) to 448 (SD=565) minutes (p=0.003). In contrast, the control group had neither diminished pain (p=0.65) nor decreased overall time experiencing pain (p=0.49). A pain decrement response seen by the tenth treatment session was predictive of final efficacy. Conclusions: These results confirm that mirror therapy is an effective therapy for phantom limb pain in unilateral, upper extremity male amputees, reducing both severity and duration of daily episodes.
- 7 July 2017
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 8, 267
Open AccessA Randomized, Controlled Trial of Mirror Therapy for Upper Extremity Phantom Limb Pain in Male Amputees
Objective: Phantom limb pain is prevalent in patients post-amputation and is difficult to treat. We assessed the efficacy of mirror therapy in relieving phantom limb pain in unilateral, upper extremity male amputees. Methods: Fifteen participants from Walter Reed and Brooke Army Medical Centers were randomly assigned to one of two groups: mirror therapy (n=9) or control (n=6, covered mirror or mental visualization therapy). Participants were asked to perform 15 minutes of their assigned therapy daily for 5 days/week for four weeks. The primary outcome was pain as measured using a 100-mm Visual Analogue Scale (VAS). Results: Subjects in the mirror therapy group had a significant decrease in pain scores, from a mean of 44.1 (SD=17.0) to 27.5 (SD=17.2) mm (p=0.002). In addition, there was a significant decrease in daily time experiencing pain, from a mean of 1022 (SD=673) to 448 (SD=565) minutes (p=0.003). In contrast, the control group had neither diminished pain (p=0.65) nor decreased overall time experiencing pain (p=0.49). A pain decrement response seen by the tenth treatment session was predictive of final efficacy. Conclusions: These results confirm that mirror therapy is an effective therapy for phantom limb pain in unilateral, upper extremity male amputees, reducing both severity and duration of daily episodes.